Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients
New hope for tough lymphoma cases
A retrospective two-center cohort of 27 heavily treated patients with relapsed/refractory non-GCB DLBCL evaluated zanubrutinib-combined ther…
Combining zanubrutinib with other treatments helped 74% of patients with tough, hard-to-treat lymphoma respond after standard options failed…